Thursday, 15 October 2026European Markets

ASR NEDERLAND, CRCAM BRIE PIC2CCI, Another 2 Companies Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - asr nederland (asrnl.as) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
asr nederland (asrnl.as) €40.95 6.54% 10.26%
crcam brie pic2cci (crbp2.pa) €18.13 5.62% 4.04%
axa (cs.pa) €26.97 5.44% 10.69%
rothschild & co (roth.pa) €38.65 3.62% 18.96%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. asr nederland (asrnl.as)

6.54% forward dividend yield and 10.26% return on equity

asr nederland n.v. provides insurance, pensions, and mortgages products for consumers, self-employed persons, and companies. it operates through five segments: non-life, life, asset management, distribution and services, and holding and other. the company offers health, life, pension, funeral expense, and occupational disability insurance products; and non-life insurance products, including road traffic, fire, third-party liability and legal assistance insurance. it also provides financial intermediary services; and develops real estate properties, as well as operates as an asset manager for third parties. asr nederland n.v. offers its products under the loyalis, ditzo, europeesche verzekeringen, a.s.r. asset management, ardanta, and a.s.r. brand names. the company was formerly known as fortis verzekeringen nederland n.v. and changed its name to asr nederland n.v. in october 2008. asr nederland n.v. was founded in 1720 and is headquartered in utrecht, the netherlands.

earnings per share

as for profitability, asr nederland has a trailing twelve months eps of €4.42.

pe ratio

asr nederland has a trailing twelve months price to earnings ratio of 9.26. meaning, the purchaser of the share is investing €9.26 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.26%.

more news about asr nederland.

2. crcam brie pic2cci (crbp2.pa)

5.62% forward dividend yield and 4.04% return on equity

caisse régionale de crédit agricole mutuel brie picardie société coopérative provides a range of banking and financial products and services to individuals, farmers, professionals, businesses, and local authorities in france. it offers savings support comprising monetary, bonds, and securities; and life insurance investments, as well as housing and consumer loans; payment services; and property and casualty insurance, provident insurance products, and life insurance products. the company was founded in 2005 and is headquartered in amiens, france. caisse régionale de crédit agricole mutuel brie picardie société coopérative is a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam brie pic2cci has a trailing twelve months eps of €11.26.

pe ratio

crcam brie pic2cci has a trailing twelve months price to earnings ratio of 1.61. meaning, the purchaser of the share is investing €1.61 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.04%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, crcam brie pic2cci's stock is considered to be oversold (<=20).

moving average

crcam brie pic2cci's value is higher than its 50-day moving average of €18.09 and under its 200-day moving average of €18.35.

more news about crcam brie pic2cci.

3. axa (cs.pa)

5.44% forward dividend yield and 10.69% return on equity

axa sa, through its subsidiaries, provides insurance, asset management, and banking services worldwide. the company operates through six segments: france, europe, asia, axa xl, international, and transversal & central holdings. it offers life and savings insurance products, such as savings and retirement, other health, and personal protection products. the company also provides property and casualty insurance products, including car, home, and personal or professional liability to individual and business clients; international insurance for large corporate clients in europe; and marine and aviation insurance services, as well as property and casualty reinsurance products. in addition, it offers asset management services in the areas of various asset classes, including equities, bonds, hedge funds, private equity, and real estate for the group's insurance companies and their clients, and retail and institutional clients. further, the company provides health, term life, whole life, universal life, endowment, and other investment-based products for personal/individual and commercial/ group customers. axa sa was founded in 1852 and is headquartered in paris, france.

earnings per share

as for profitability, axa has a trailing twelve months eps of €2.83.

pe ratio

axa has a trailing twelve months price to earnings ratio of 9.53. meaning, the purchaser of the share is investing €9.53 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.69%.

more news about axa.

4. rothschild & co (roth.pa)

3.62% forward dividend yield and 18.96% return on equity

rothschild & co sca provides global advisory, wealth and asset management, and merchant banking services in france, the united kingdom, the channel islands, the americas, rest of europe, switzerland, australia, asia, and internationally. the company offers merger and acquisition, and strategic advisory solutions; debt advisory and restructuring services; and equity advisory services, such as equity capital markets (ecm) advisory, private capital, and investor advisory and marketing services. it also provides wealth management services to successful families, individuals, foundations, and charities; and asset management services comprising bespoke investment management and advisory services to institutional clients, financial intermediaries, and third-party distributors. in addition, the company offers merchant banking services, including corporate private equity, multi strategies, direct lending, and credit management. rothschild & co sca was founded in 1838 and is headquartered in paris, france.

earnings per share

as for profitability, rothschild & co has a trailing twelve months eps of €8.27.

pe ratio

rothschild & co has a trailing twelve months price to earnings ratio of 4.67. meaning, the purchaser of the share is investing €4.67 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.96%.

volume

today's last reported volume for rothschild & co is 25 which is 99.98% below its average volume of 175205.

moving average

rothschild & co's worth is way below its 50-day moving average of €43.17 and way under its 200-day moving average of €42.96.

revenue growth

year-on-year quarterly revenue growth declined by 9.3%, now sitting on 2.93b for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, rothschild & co's stock is considered to be oversold (<=20).

more news about rothschild & co.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com